EU approval for self-administered Crysvita
Crysvita is used to treat the rare genetic condition X-linked hypophosphataemia
Read Moreby Lucy Parsons | Jul 20, 2021 | News | 0
Crysvita is used to treat the rare genetic condition X-linked hypophosphataemia
Read Moreby Lucy Parsons | Oct 5, 2020 | News | 0
New approval includes older adolescents and adults with rare disease
Read Moreby Selina McKee | Jul 28, 2020 | News | 0
The decision could see older adolescents and adults access the treatment for X-linked hypophosphataemia (XLH)
Read Moreby Selina McKee | Oct 10, 2018 | News | 0
For the first time in more than 30 years children and young adults in England and Wales with the rare bone disorder XLH will have access to a new treatment option via the NHS.
Read Moreby Selina McKee | Sep 5, 2018 | News | 0
The National Institute for Health and Care Excellence (NICE) has changed its position on NHS funding for Kyowa Kirin International’s Crysvita, now endorsing the drug’s use to treat X-linked hypophosphataemia (XLH) in children and young people with growing bones in England and Wales.
Read Moreby Selina McKee | Jun 15, 2018 | News | 0
Children and young people with X-linked hypophosphataemia (XLH) are unlikely to get routine access to Kyowa Kirin’s Crysvita on the NHS.
Read Moreby Selina McKee | Apr 19, 2018 | News | 0
US regulators have approved the first drug to treat adults and children with x-linked hypophosphatemia (XLH), a rare, inherited form of rickets.
Read Moreby Selina McKee | Feb 26, 2018 | News | 0
Doctors can now treat children living in the EU with the rare, chronic progressive musculoskeletal disorder X–Linked Hypophosphataemia with Kyowa Kirin/Ultragenyx’ Crysvita following its conditional approval in the region.
Read Moreby Selina McKee | Dec 18, 2017 | News | 0
Seven therapies have been put forward for approval in the European Union, bringing closer new options for a range of conditions including Crohn’s disease, diabetes and cancer.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
